An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)

Bruyère, Olivier; Honvo, Germain; Veronese, Nicola; Arden, N K; Branco, Jaime; Curtis, Elizabeth M; Al-Daghri, Nasser M.; Herrero‐Beaumont, Gabriel; Martel‐Pelletier, Johanne; Pelletier, Jean Pierre; Rannou, François; Rizzoli, René; Roth, Roland; Uebelhart, Daniel; Cooper, Cyrus; Reginster, Jean Yves

doi:10.1016/j.semarthrit.2019.04.008

Cited by 426 publications

(482 citation statements)

References 168 publications

Supporting

Mentioning

371

Contrasting

Unclassified

102

Order By: Relevance

“…Consequently, when analgesic benefit is uncertain and with increasing safety issues, more careful consideration of paracetamol use is required. The ESCEO algorithm recommends that paracetamol be used as short-term rescue analgesia only (dose ≤ 3 g/day) given on top of a background of SYSADOAs [4].…”

Section: Paracetamolmentioning

confidence: 99%

“…Thus, among the SYSADOA products available, pharmaceutical-grade pCGS and CS are strongly recommended by the ESCEO as first-line SYSADOAs, for which the evidence base is unequivocal [4]. Other SYSADOAs (diacerein and ASU) may be used as alternative step 1 background therapy; however, the evidence for their efficacy and safety is scarcer than that of CS and pCGS.…”

Section: Sysadoasmentioning

confidence: 99%

“…The results of these safety meta-analyses were included alongside the literature search results in the analysis and formulation of revised guidelines, which are summarized in the modified treatment algorithm (Fig. 1) [4]. While it is recognized that OA management practices can vary slightly between "Western" and "Central" Europe, the ESCEO guidelines, which were originally drafted by a panel of physicians mainly from Western Europe, are also endorsed by the Central European authors here.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis

et al. 2019

Self Cite

View full text Add to dashboard Cite

Osteoarthritis (OA) is characterized by deterioration of the joints and associated with considerable pain and disability. OA is a chronic disease that requires intervention with both non-pharmacological and pharmacological treatment modalities and, inevitably, disease progression may necessitate successive treatments throughout the course of the disease. There is increasing data on the shortfalls of current pharmacological treatment of OA, and safety concerns associated with analgesic therapy use in OA arising from increasing evidence of gastrointestinal, cardiovascular, hepatic and renal adverse events with paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs). Consequently, symptomatic slow-acting drugs for OA (SYSADOAs) may now be considered as a first-line treatment for knee OA, with a particular emphasis placed on the outstanding benefit: risk ratio of pharmaceutical-grade glucosamine and chondroitin sulfate formulations. In this short communication we review recent publications concerned with the safety of paracetamol, NSAIDs and SYSADOAs. Greater understanding of the benefits and limitations of current medications will lead to better disease management in OA. Furthermore, adherence to guideline recommendations across Europe and internationally, such as those from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), will promote evidence-based medicine and patient-centric care, ultimately leading to greater physician and patient satisfaction.

show abstract

Section: Paracetamolmentioning

confidence: 99%

Section: Sysadoasmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Рекомендации по лечению ОА коленных суставов для реальной клинической практики были созданы Европейским обществом по клиническим и экономическим аспектам остеопороза и остеоартрита (ESCEO) [23], в них было представлено пошаговое назначение различных лекарственных методов, в 2019 г. эти рекомендации были обновлены (рис. 5) [24]. Еще раз была подчеркнута необходимость комплексного немедикаментозного и медикаментозного лечения ОА.…”

Section: рис 3 новое определение остеоартритаunclassified

“…Гликозаминогликан-пептидный комплекс (Румалон), имеющий в своем составе фармакологически качественный ХС, при внутримышечном введении обларис. 5. esceo алгоритм рекомендаций для лечения остеоартрита [24] комбинация немедикаментозных и фармакологических методов основной набор: образование, снижение веса, лечебная физкультура дает выраженным действием на симптоматику ОА, а при длительном применении -замедляет прогрессию болезни (рис. 6-8) [27][28][29][30][31][32][33][34].…”

Section: рис 3 новое определение остеоартритаunclassified

New ideas about the pathogenesis of osteoarthritis, the role of metabolic disorders

Алексеева¹

2019

Obes. metabol.

View full text Add to dashboard Cite

The article highlights the current data on the prevalence and pathogenesis of osteoarthritis (OA), presents a new definition of the disease, research results on the heterogeneity of OA, its relationship with obesity and metabolic syndrome. Obesity is one of the main factors in the development and more rapid progression of OA, and the presence of metabolic syndrome not only increases the risk of developing the disease, but also determines its severity. It is noted that with an increase of the components of the metabolic syndrome, the severity of OA increases. Therefore, hyperuricemia is associated with the presence of osteophytes and the progression of osteoarthritis, hyperglycemia - with the severity of the clinical manifestations and radiological progression. Much attention is given to the treatment of patients with OA and The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) recommendations for the treatment of knee joints OA updated in 2019. In which for the first time a symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) are assigned as the basis in the treatment of OA. The data on the effectiveness of some drugs from this group are presented. The glycosaminoglycan-peptide complex, which contains pharmacologically high-quality chondroitin sulfate when administered intramuscularly, has a significant effect on the symptoms, and in case of continued use, slows the progression of OA. The multicenter open-label prospective study of diacerein in patients with knee-joint OA combined with metabolic syndrome showed that during therapy pain syndrome and stiffness are reduced, and functional condition of the joints and quality of life of patients improves quickly and significantly. In addition, the positive effect of the drug on some components of the metabolic syndrome was demonstrated: a significant decrease in body mass index, low density lipoproteins, triglycerides, glucose and uric acid.

show abstract

Effect of Prehabilitation Before Total Knee Replacement for Knee Osteoarthritis on Functional Outcomes

et al. 2022

Self Cite

View full text Add to dashboard Cite

IMPORTANCE Multidisciplinary prehabilitation before total knee replacement (TKR) for osteoarthritis may improve outcomes in the postoperative period. OBJECTIVE To compare multidisciplinary prehabilitation with usual care before TKR for osteoarthritis in terms of functional independence and activity limitations after surgery. DESIGN, SETTING, AND PARTICIPANTSThis prospective, open-label randomized clinical trial recruited participants 50 to 85 years of age with knee osteoarthritis according to the American College of Rheumatology criteria for whom a TKR was scheduled at 3 French tertiary care centers.

show abstract

An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)

Cited by 426 publications

References 168 publications

Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis

Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis

New ideas about the pathogenesis of osteoarthritis, the role of metabolic disorders

Effect of Prehabilitation Before Total Knee Replacement for Knee Osteoarthritis on Functional Outcomes

Contact Info

Product

Resources

About